Emr Serano Ms201964-0001- A Multicenter, Open-Label, Dose Escalation Phase I Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of The Dna-Pk Inhibitor M3814 In Combination With Avelumab With And Without Palliative Radiotherapy In Participan
Posted Date: May 22, 2020
- Investigator: Davendra Sohal
- Specialties: Cancer, Oncology
- Type of Study: Drug
The goal for this study is To determine a safe, tolerable, RP2D and/or the MTD of M3814 when given in combination with avelumab, as well as evaluate safety and preliminary antitumor activity of M3814 in combination with avelumab.
Criteria:
To Be Eligible: Must Have Advanced Or Metastatic Solid Tumor For Which No Standard Therapy Exists, Measurable Disease, Ecog 0-1, No Cardiovascular Disease Or Uncontrolled Intercurrent Illness, No Active Infection, No Previous Malignancy Within 5 Years,
Keywords:
Phase 1, Advanced Tumors
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com